• R1 Therapeutics raises $77.5M Series A to advance kidney disease drug
DaVita Venture Group - Latest News and Investment Deals
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

Top Publishers

Top Creators

  • Ryan Allis

    Ryan Allis

    194 followers

  • Elon Musk

    Elon Musk

    78 followers

  • Sam Altman

    Sam Altman

    68 followers

  • Mark Cuban

    Mark Cuban

    56 followers

  • Jack Dorsey

    Jack Dorsey

    39 followers

See More →

Top Companies

  • SaasRise

    SaasRise

    196 followers

  • Anthropic

    Anthropic

    39 followers

  • OpenAI

    OpenAI

    21 followers

  • Hugging Face

    Hugging Face

    15 followers

  • xAI

    xAI

    12 followers

See More →

Top Investors

  • Andreessen Horowitz

    Andreessen Horowitz

    16 followers

  • Y Combinator

    Y Combinator

    15 followers

  • Sequoia Capital

    Sequoia Capital

    12 followers

  • General Catalyst

    General Catalyst

    8 followers

  • A16Z Crypto

    A16Z Crypto

    5 followers

See More →
NewsDealsSocialBlogsVideosPodcasts
HomeDaVita Venture Group
DaVita Venture Group logo

DaVita Venture Group

0 followers

About DaVita Venture Group

DaVita Venture Group partners with health care innovators to invest in, acquire, and co-develop products, solutions, and businesses that improve care for patients with kidney disease and related conditions. The group focuses on care delivery models, life sciences, and digital health to expand access to care and improve clinical outcomes, leveraging tech-enabled services, home treatments, and value-based care. As the corporate venture arm tied to DaVita, it accelerates strategy through strategic investing, corporate development, and partnerships to bring new technologies to market. Based in the United States, the group collaborates with startups and established companies to transform patient care.

Recent News

No recent news for this company.

Recent Deals

R1 Therapeutics Raises $77.5M Series A to Advance Kidney Disease Drug

March 18, 2026

Key Team Members

Mahesh Krishnan, MD, MPH, MBA, FASN

Group Vice President, Research and Development

Steve Phillips

Group Vice President, Strategy and Innovation

Brad Marzullo

Vice President – M&A and Strategic Partnerships

Tom Musgrave

Vice President, Pharma Strategy and Contracting

Allison Donovan

Group General Counsel, DaVita Venture Group

Key Facts

HQ Location

Denver, United States

Founded

2019

Employees

11 - 50

Status

Investor

Investor Type

Corporate Investor

Website

https://davitaventuregroup.com